People Round-Up: Bhadauria Named As Amneal CSO

Amneal gets a new CSO, Acino restructures its board under a new chair, the AAM adds an assistant general counsel and the British Biosimilars Association names a vice-chair, as well as other people movements from around the generics, biosimilars and value-added medicines industries.

People
• Source: Shutterstock

Amneal Pharmaceuticals Inc. has named former Apotex vice-president of global R&D, Pradeep Bhadauria, as Amneal’s chief scientific officer with immediate effect, succeeding current CSO Shankar Hariharan who will leave the company on 24 May. Citing Bhadauria’s “significant R&D expertise” – with over 20 years of experience leading development for generics and specialty pharmaceutical firms including Actavis – Amneal said he had overseen the development and filing of more than 200 products, “including numerous first-to-file and first-to-market opportunities”. In particular, noted Amneal’s president and CEO, Rob Stewart, Bhadauria had “demonstrated strength in developing complex generics and other difficult-to-formulate products”, which would be “a strong asset to our company as we continue to diversify our pipeline and portfolio”.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Leadership

More from Generics Bulletin

Sandoz And Henlius Join Forces With $300m Ipilimumab Deal

 
• By 

Sandoz has struck a deal worth up to $301m with Henlius giving it rights to a proposed ipilimumab biosimilar to Yervoy in countries across the world.

Discounted Ustekinumab Biosimilars Further Dent J&J’s Q1 Stelara Sales

 

With discounts reaching up to 90%, ustekinumab biosimilars have eroded originator Stelara’s sales as expected. In its latest quarterly biosimilar market report, Samsung Bioepis also analyzed the latest regulatory steps to streamline biosimilar development.

Speranza Starts Generics Offshoot In Response To Wider US Pharma Manufacturing Drive

 
• By 

Reflecting increased regulatory pressure and a wider drive towards the reshoring of pharmaceutical manufacturing to the US, Speranza has launched a new generics business called Lotus Therapeutics.